| Obiyo O Osuchukwu, MBBCH MPH | |
|
22 Bramhall St, Portland, ME 04102-3175 | |
| (469) 288-1521 | |
| Not Available |
| Full Name | Obiyo O Osuchukwu |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Location | 22 Bramhall St, Portland, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477901478 | NPI | - | NPPES |
| 1477901478 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD25006 (Maine) | Primary |
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245252212 PECOS PAC ID: 7618871245 Enrollment ID: O20040127000198 |
News Archive
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented at the 2011 European Multidisciplinary Cancer Congress.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
Previous reports from the group at Mayo Clinic have demonstrated that B7-H1 expression by renal cell carcinoma (RCC) is a marker of poor prognosis in both localized and metastatic RCC.
University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.
› Verified 8 days ago
| Entity Name | Spectrum Healthcare Partners Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245252212 PECOS PAC ID: 7618871245 Enrollment ID: O20040915000845 |
News Archive
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented at the 2011 European Multidisciplinary Cancer Congress.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
Previous reports from the group at Mayo Clinic have demonstrated that B7-H1 expression by renal cell carcinoma (RCC) is a marker of poor prognosis in both localized and metastatic RCC.
University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Obiyo O Osuchukwu, MBBCH MPH 22 Bramhall St, Portland, ME 04102-3175 Ph: (207) 662-2526 | Obiyo O Osuchukwu, MBBCH MPH 22 Bramhall St, Portland, ME 04102-3175 Ph: (469) 288-1521 |
News Archive
Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.
Many prostate cancer patients develop bone metastases, and controlling the pain these cause can be difficult. Now the first large randomised Phase III trial of a bisphosphonate drug in these patients has shown that a single dose of the drug is as good for pain relief as single dose radiotherapy, the standard treatment for bone metastases. Results of the trial were presented at the 2011 European Multidisciplinary Cancer Congress.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
Previous reports from the group at Mayo Clinic have demonstrated that B7-H1 expression by renal cell carcinoma (RCC) is a marker of poor prognosis in both localized and metastatic RCC.
University of British Columbia scientists, in collaboration with an industry partner, have successfully reversed diabetes in mice using stem cells, paving the way for a breakthrough treatment for a disease that affects nearly one in four Canadians.
› Verified 8 days ago
David Edward Landry, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 | |
Francis Altman, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 144 State St, Anesthesia Department, Portland, ME 04101 Phone: 207-879-3385 | |
Dylan Wingfield, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-478-6024 | |
Dr. Frederick Craig Littlejohn, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1945 Congress St Ste 103, Portland, ME 04102 Phone: 207-835-8116 | |
Christopher James Beeler, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 | |
Charles F Adams, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-2526 | |
Jeffrey Morse, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 144 State St, Anesthesia Department, Portland, ME 04101 Phone: 207-879-3385 |